Pfizer mentioned Wednesday that it’s going to present practically two dozen merchandise, together with its top-selling COVID-19 vaccine and remedy, at not-for-profit costs in among the world’s poorest international locations.
The drugmaker introduced this system on the World Financial Discussion board’s annual gathering in Davos, Switzerland, and mentioned it was geared toward bettering well being fairness in 45 lower-income international locations. Many of the international locations are in Africa, however the listing additionally contains Haiti, Syria, Cambodia and North Korea.
The merchandise, that are broadly obtainable within the U.S. and the European Union, embrace 23 medicines and vaccines that deal with infectious illnesses, some cancers and uncommon and inflammatory situations. Firm spokes Pam Epersonisele mentioned solely a small variety of the medicines and vaccines are presently obtainable within the 45 international locations.
New York-based Pfizer will cost solely manufacturing prices and “minimal” distribution bills, Eisele mentioned. It should adjust to any sanctions and all different relevant legal guidelines.
The drugmaker additionally plans to offer assist with public training, coaching for well being care suppliers and drug provide administration.
“What we found by means of the pandemic was that provide was not sufficient to resolve the problems that these international locations are having,” Pfizer Chairman and CEO Albert Bourla mentioned Wednesday throughout a chat at Davos.
He famous that billions of doses of the corporate’s COVID-19 vaccine, Comirnaty, have been supplied totally free to low-income international locations, primarily by means of the U.S. authorities, however these doses cannot be used proper now.
Earlier this month, the top of the World Well being Group known as on Pfizer to make its COVID-19 remedy extra broadly obtainable in poorer international locations.
Comirnaty introduced in practically $37 billion US in gross sales final yr, and analysts count on the corporate’s COVID-19 remedy Paxlovid so as to add nearly $24 billion US this yr, in response to the info agency FactSet.